Condition
Pediatric Hypertension
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
80%
4 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results80% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 3 (3)
P 4 (1)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03461003Phase 4CompletedPrimary
N-of-1 Trials In Children With Hypertension
NCT03783650Not ApplicableTerminatedPrimary
Boosting Primary Care Awareness and Treatment of Childhood Hypertension
NCT02791438Phase 3CompletedPrimary
A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
NCT02451150Phase 3CompletedPrimary
A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension
NCT00244634Phase 3CompletedPrimary
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
Showing all 5 trials